Iovance Biotherapeutics Inc at JMP Securities Life Sciences Virtual Conference Transcript
Excellent. Good afternoon, everyone, and welcome to the second day of the JMP Securities Life Sciences Conference. My name is Ren Benjamin, Senior Biotechnology Analyst here. And it's my pleasure to introduce Iovance, in our view, the leader in TIL therapies for solid tumors and a company that's on the cusp of submitting multiple BLAs. Here to tell us more about the company is Igor Bilinsky, COO; and Sara Pellegrino, VP of IR. Welcome, guys, nice to see you. We never really know exactly who's in the audience, whether they know of the Iovance story or not. And so Sara, maybe I'll hand it off to you to give us a quick synopsis of the Iovance story as a whole.
Sure, and thanks so much, Reni, for hosting us today. So Iovance is a late-stage oncology company. We're developing novel cell therapies initially focused on addressing solid tumors for patient populations with significant unmet need.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
